United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $580.36, for a total value of $5,513,420.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $23,512,124.68. The trade was a 19.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

United Therapeutics Stock Performance

UTHR stock traded up $2.93 on Thursday, reaching $580.51. The company had a trading volume of 446,672 shares, compared to its average volume of 497,137. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89. The company’s fifty day moving average is $522.64 and its 200 day moving average is $487.71. The company has a market cap of $25.44 billion, a P/E ratio of 20.81, a PEG ratio of 1.65 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same quarter in the prior year, the company earned $6.19 EPS. United Therapeutics’s revenue was up 7.4% on a year-over-year basis. On average, sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in UTHR. AE Wealth Management LLC increased its holdings in United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC increased its holdings in United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after purchasing an additional 2,975 shares in the last quarter. Optimize Financial Inc acquired a new stake in United Therapeutics in the 3rd quarter valued at $444,000. Simplify Asset Management Inc. acquired a new stake in United Therapeutics in the 3rd quarter valued at $8,351,000. Finally, Osaic Holdings Inc. increased its holdings in United Therapeutics by 271.0% in the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock valued at $14,027,000 after purchasing an additional 33,662 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on UTHR shares. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. HC Wainwright upped their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Morgan Stanley upped their target price on United Therapeutics from $471.00 to $519.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Ten analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $601.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.